Liquidia (LQDA) shares climbed more than 14% in recent Monday trading after the US Supreme Court denied a request by United Therapeutics (UTHR) for a review of previous rulings over a patent infringement dispute between the two companies.
The high court's rejection of United Therapeutic's petition means that the US Court of Appeals for the Federal Circuit's 2023 ruling affirming the decision of Patent Trial and Appeal Board in 2022 against United Therapeutics' patent claims is "final and not subject to further appeal," Liquidia said
The board had ruled against United Therapeutics' patent covering claims related to Liquidia's Yutrepia, or treprostinil, inhalation powder to treat adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
Liquidia said the US Food and Drug Administration's final approval for Yutrepia may occur after the three-year regulatory exclusivity for United Therapeutics' Tyvaso DPI for the treatment of similar ailment expires on May 23 next year.
United Therapeutics did not immediately reply to MT Newswires' request for comment. Its shares were down about 1%.
Price: 11.51, Change: +1.48, Percent Change: +14.71
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。